FDA approves pancreatic cancer drug that extends patients’ lives
The Food and Drug Administration approved daraxonrasib, sold under the brand name Rasonque, to treat metastatic pancreatic adenocarcinoma in patients unable to tolerate multiagent systemic therapy. The targeted treatment directs attention to RAS(ON) proteins to inhibit tumor progression. Clinical evidence demonstrates that the therapy increases median overall survival to 13.2 months from 6.7 months and improves median progression-free survival to 7.2 months from 3.6 months. The regulatory decision follows extensive development efforts focused on managing this difficult cancer driver.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The Food and Drug Administration approved daraxonrasib, sold as Rasonque, for metastatic pancreatic adenocarcinoma patients who cannot tolerate multiagent systemic therapy.
- ✓ Clinical data indicates the treatment doubles median overall survival from 6.7 to 13.2 months.
- ✓ The therapy increases median progression-free survival from 3.6 to 7.2 months by targeting RAS(ON) proteins.
What changed
The Food and Drug Administration officially approved the drug daraxonrasib for eligible metastatic pancreatic adenocarcinoma patients.
Live updates
-
FDA Approves Daraxonrasib for Pancreatic Cancer
The Food and Drug Administration approved daraxonrasib, sold under the brand name Rasonque, to treat metastatic pancreatic adenocarcinoma in patients unable to tolerate multiagent systemic therapy. The targeted treatment directs attention to RAS(ON) proteins to inhibit tumor progression. Clinical evidence demonstrates that the therapy increases median overall survival to 13.2 months from 6.7 months and improves median progression-free survival to 7.2 months from 3.6 months. The regulatory decision follows extensive development efforts focused on managing this difficult cancer driver.
Why it matters
Pancreatic cancer remains among the deadliest forms of malignant disease, historically offering limited therapeutic options for advanced patients. The approval marks a major development in addressing the notoriously elusive RAS driver following years of foundational science and public funding. Medical professionals continue to evaluate the long-term impact of targeting these specific cellular pathways in clinical care.
What is confirmed
- The Food and Drug Administration approved daraxonrasib, sold as Rasonque, for metastatic pancreatic adenocarcinoma patients who cannot tolerate multiagent systemic therapy.
- Clinical data indicates the treatment doubles median overall survival from 6.7 to 13.2 months.
- The therapy increases median progression-free survival from 3.6 to 7.2 months by targeting RAS(ON) proteins.
Still unconfirmed
- Researchers question whether a definitive cure for pancreatic cancer will ever be found following the introduction of targeted therapies.
What to watch next
- Further clinical data on RAS(ON) protein inhibitors
- Patient uptake and post-market safety monitoring for Rasonque
confidence 100%Sources used for this update (16)
- en.wikipedia.org — Food and Drug Administration - Wikipedia
- www.usa.gov — Food and Drug Administration (FDA) | USAGov
- www.fda.gov — What We Do | FDA
- www.fda.gov — About FDA | FDA - U.S. Food and Drug Administration
- www.wral.com — Business News and Reporting Coverage, page 34 | WRAL
- www.physiciansweekly.com — Q&A: Daraxonrasib's Impact on Pancreatic Cancer Research ...
- www.thetechedvocate.org — This AI-Engineered CAR T Therapy Is a Game-Changer for Cancer Patients
- www.techtimes.com — GE HealthCare Pays $945M for PET Tracer Network That Radioactive Decay Made Irreplaceable - Tech Times
- www.targetedonc.com — Prostate and Rare Cancer Agents Nab FDA Fast Track Status
- www.curetoday.com — 5 Years of Liver Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
- pancan.org — Pancreatic Cancer Action Network – Research, Patient Support, Resources
- letswinpc.org — Let’s Talk About Rasonque: a Q&A for Our Community
-
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
The FDA approved daraxonrasib, sold as Rasonque, for patients with metastatic pancreatic adenocarcinoma who cannot tolerate multiagent systemic therapy. The drug targets RAS(ON) proteins to stop tumor growth. Clinical data indicates the treatment doubles median overall survival from 6.7 to 13.2 months and increases median progression-free survival from 3.6 to 7.2 months. This approval follows decades of basic science and public funding aimed at targeting the elusive RAS driver in one of the deadliest forms of cancer.
Why it matters
Pancreatic cancer is historically difficult to treat due to the elusive nature of its primary drivers. Daraxonrasib represents a shift in capability by successfully targeting a mutation previously considered undruggable. The Christ Hospital Health Network contributed to this development by enrolling the second patient in the clinical trial.
What is confirmed
- The FDA approved daraxonrasib, marketed as Rasonque, for treating metastatic pancreatic adenocarcinoma in patients unable to tolerate multiagent systemic therapy.
- Daraxonrasib doubles median overall survival from 6.7 to 13.2 months.
- Median progression-free survival increases from 3.6 to 7.2 months with the drug.
- The drug inhibits tumor growth by targeting RAS(ON) proteins.
- The Christ Hospital Health Network enrolled the second patient in the clinical trial for daraxonrasib.
Still unconfirmed
- Russ Reed, 63, experienced miracle results from the new pancreatic cancer drug.
What to watch next
- Long-term survival data beyond the initial 13.2 month median overall survival.
- Expanded FDA indications for daraxonrasib in patients who can tolerate systemic therapy.
confidence 95%Sources used for this update (13)
- www.fda.gov — U.S. Food and Drug Administration
- www.fda.gov — Drugs | FDA
- www.thechristhospital.com — FDA Approves Pancreatic Cancer Drug | The Christ Hospital
- www.miragenews.com — Scientists Crack Undruggable KRAS Cancer Mutation
- www.curetoday.com — 5 Years of Breast Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
- stocktwits.com — Nike faces a major earnings test as shares plunge 44% year-to-date, and short interest reaches 87 million....
- www.medscape.com — How Scientists Finally Cracked RAS in Pancreatic Cancer - Today on Medscape
- www.cancernetwork.com — 2021 Pipeline Updates: Promising Ongoing Trials in Breast Cancer From TROP2 ADCs to Oncolytic Viruses | C....
- www.clickorlando.com — Florida man says new pancreatic cancer drug has provided miracle results
- www.newsday.com — Woodbury pediatrician bakes her way into Lustgarten Foundation's fight against pancreatic cancer - Newsda....
- www.therepublic.com — Soldiering on: Columbus veteran embraces each day after seven years with pancreatic cancer - The Republic....
- stocktwits.com — SLS Stock Snaps 3-Quarter Winning Streak — Why Retail Traders Are Watching Sellas’ Lease And AML Pipe....
-
FDA Approves Daraxonrasib for Pancreatic Cancer
The FDA has approved daraxonrasib, marketed as Rasonque, for treating metastatic pancreatic adenocarcinoma in patients who cannot tolerate multiagent systemic therapy. Clinical trials show the drug doubles median overall survival from 6.7 to 13.2 months and extends median progression-free survival from 3.6 to 7.2 months. Daraxonrasib targets RAS(ON) proteins to inhibit tumor growth.
Why it matters
Pancreatic cancer is the third deadliest cancer in the United States, often diagnosed late. Current treatments have limited effectiveness, making new therapies crucial. Daraxonrasib's approval offers hope for patients with advanced pancreatic cancer.
What is confirmed
- Daraxonrasib doubles median overall survival from 6.7 to 13.2 months.
- Daraxonrasib extends median progression-free survival from 3.6 to 7.2 months.
- The treatment costs $663 per tablet, translating to roughly $480,000 annually.
- Daraxonrasib targets RAS(ON) proteins to inhibit tumor growth.
- The FDA approved daraxonrasib for metastatic pancreatic adenocarcinoma in patients unable to tolerate multiagent systemic therapy.
What to watch next
- Takeda's presentation of new oncology pipeline data at the European Society for Medical Oncology (ESMO) Congress on October 23-27, 2026
- Further studies on synthetic lethality-based clinical trials in oncology
- Updates on the use of theranostics in cancer treatment
confidence 100%Sources used for this update (14)
- www.irishtimes.com — ‘I had no idea it was so serious’: Woman’s back and shoulder pain was pancreatic cancer
- www.segyenewsagency.com — Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-B....
- www.nature.com — Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation | Signal Tra....
- www.medicaldaily.com — Theranostics Programs Expand at Mayo Clinic, MD Anderson, and Other Centers, but Approved Uses Still Cove....
- medcitynews.com — Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder - MedCity News
- immunitybio.com — Latest News in Targeted Cell Therapies for Cancer & Infectious Diseases
- www.sharp.com — New pancreatic cancer drug offers hope - Sharp HealthCare
- www.wbur.org — How an Mass. researcher's lab made a breakthrough in pancreatic cancer treatment
- www.thetechedvocate.org — Why Millions Are Switching to This New Cancer Test Right Now
- www.onclive.com — Daraxonrasib Approval Signals a New Era for RAS-Targeted ...
- www.corporateeconomic.com — Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-B....
- www.fox8live.com — FDA approves new pill for pancreatic cancer treatment
-
FDA Approves Daraxonrasib for Pancreatic Cancer
The Food and Drug Administration approved Daraxonrasib, marketed as Rasonque and produced by Revolution Medicines, to treat metastatic pancreatic adenocarcinoma in patients unable to tolerate multiagent systemic therapy. The targeted therapy addresses RAS(ON) proteins to inhibit tumor growth. Clinical data from the RASolute 302 trial shows the drug doubles median overall survival from 6.7 to 13.2 months and extends median progression-free survival from 3.6 to 7.2 months. The treatment costs $663 per tablet, translating to roughly $480,000 annually.
Why it matters
Pancreatic cancer historically carries a poor prognosis and presents few effective treatment options for patients. The approval of Daraxonrasib marks a major milestone for patients with metastatic pancreatic adenocarcinoma who cannot use multiagent systemic therapy. Other companies, such as AIM ImmunoTech, are now highlighting potential roles for their own products like Ampligen within the evolving treatment environment.
What is confirmed
- The FDA approved Daraxonrasib, sold as Rasonque and produced by Revolution Medicines, for patients with metastatic pancreatic adenocarcinoma who cannot tolerate multiagent systemic therapy.
- The drug targets RAS(ON) proteins to inhibit tumor growth in over 90% of pancreatic cancer cases.
- Clinical data from the RASolute 302 trial shows the therapy doubles median overall survival from 6.7 to 13.2 months and median progression-free survival from 3.6 to 7.2 months.
- The drug costs $663 per tablet, or roughly $480,000 annually.
Still unconfirmed
- AIM ImmunoTech highlighted Ampligen's potential role and clinical potential in the evolving pancreatic cancer treatment environment following the FDA approval of Revolution Medicines' drug.
What to watch next
- Further clinical data presentations for competing oncology treatments at the European Society for Medical Oncology Congress in October 2026.
- Additional corporate positioning and trial updates from companies evaluating combination or alternative pancreatic cancer therapies.
confidence 100%Sources used for this update (3)
- www.afp.com — Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
- www.galvnews.com — Hope for those with pancreatic cancer
- www.finanznachrichten.de — AIM ImmunoTech Inc.: AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolu…
-
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
The FDA approved Daraxonrasib, sold as Rasonque, for patients with metastatic pancreatic adenocarcinoma who cannot tolerate multiagent systemic therapy. Produced by Revolution Medicines, the drug targets RAS(ON) proteins to inhibit tumor growth in over 90% of pancreatic cancer cases. Clinical data from the RASolute 302 trial indicates the therapy doubles median overall survival from 6.7 to 13.2 months and median progression-free survival from 3.6 to 7.2 months. The drug costs $663 per tablet, or roughly $480,000 annually.
Why it matters
Pancreatic cancer often involves KRAS mutations that drive tumor progression. This approval provides a targeted pharmacological option for a patient population with limited treatment alternatives.
What is confirmed
- The FDA approved Daraxonrasib, marketed as Rasonque, for metastatic pancreatic adenocarcinoma.
- The drug targets RAS(ON) proteins to stop tumor growth in more than 90% of pancreatic cancer cases.
- RASolute 302 trial data shows median overall survival increased from 6.7 to 13.2 months.
- Median progression-free survival increased from 3.6 to 7.2 months.
- Revolution Medicines prices the drug at $663 per tablet, totaling approximately $480,000 per year.
What to watch next
- Insurance coverage determinations for Rasonque
- Long-term survival data beyond the RASolute 302 trial period
confidence 100%Sources used for this update (2)
- www.omanobserver.om — I lost 3 brothers to cancer. I’m determined not to be next
- note.com — What are RAS/KRAS? A Specialist Explains Why They Are Important in Pancreatic Cancer
-
FDA approves first-in-class RAS inhibitor for pancreatic cancer
The FDA approved Daraxonrasib, marketed as Rasonque, for metastatic pancreatic adenocarcinoma. The drug targets RAS(ON) proteins to stop tumor growth in more than 90% of pancreatic cancer cases. Data from the RASolute 302 trial shows the therapy extends median overall survival from 6.7 to 13.2 months and median progression-free survival from 3.6 to 7.2 months. Revolution Medicines prices the drug at $663 per tablet, totaling approximately $480,000 per year. It provides an option for patients unable to undergo multiagent systemic therapy.
Why it matters
Pancreatic cancer has historically been difficult to target pharmacologically. Daraxonrasib is the first RAS inhibitor approved to address the molecular pathway driving most of these cancers.
What is confirmed
- Daraxonrasib extends median overall survival from 6.7 to 13.2 months.
- The drug targets RAS(ON) proteins in over 90% of pancreatic cancer cases.
- Revolution Medicines prices the therapy at $663 per tablet or roughly $480,000 annually.
- The RASolute 302 trial showed median progression-free survival rose from 3.6 to 7.2 months.
Still unconfirmed
- Daraxonrasib may treat lung cancer based on early trials.
- Some users face delays of several weeks for insurance coverage.
What to watch next
- Clinical trial results for lung cancer applications.
- Insurance coverage updates for Rasonque.
confidence 90%Sources used for this update (4)
- www.sandiegouniontribune.com — San Diego Union-Tribune
- www.2minutemedicine.com — Daraxonrasib extends survival in metastatic pancreatic cancer
- www.quiverquant.com — Quiver News
- www.cancernetwork.com — All News
-
Rasonque shows potential for treatment-resistant lung cancer
Early trials suggest Daraxonrasib, marketed as Rasonque, may treat lung cancer in addition to its FDA-approved use for metastatic pancreatic adenocarcinoma. The drug targets RAS(ON) proteins to stop tumor growth in over 90% of pancreatic cancer cases, extending median survival from 6.7 months to 13.2 months. Revolution Medicines prices the therapy at $663 per tablet, or roughly $480,000 annually. While the drug offers a path for patients who cannot receive multiagent systemic therapy, some users face delays of several weeks for insurance coverage.
Why it matters
Pancreatic cancer has historically been difficult to treat due to previously undruggable proteins. Rasonque represents a shift toward precise genomic medicine. This development aligns with a 2026 American Association for Cancer Research report citing breakthroughs in translational research to reduce cancer mortality.
What is confirmed
- Rasonque is a RAS(ON) multi selective inhibitor that increases median survival for metastatic pancreatic adenocarcinoma patients from 6.7 months to 13.2 months.
- The drug stops tumor growth in over 90% of cases.
- Revolution Medicines priced Rasonque at $663 per tablet or approximately $480,000 per year.
Still unconfirmed
- Daraxonrasib is showing promise in early trials for the treatment of lung cancer.
- Some patients report that insurance coverage for Rasonque takes weeks to become available.
What to watch next
- Results from lung cancer clinical trials
- FDA expansion of Rasonque's approved indications
- Updates on insurance coverage accessibility for patients
confidence 90%Sources used for this update (5)
- www.medicalnewstoday.com — Pancreatic cancer drug may also help fight treatment-resistant lung cancer
- labusinessjournal.com — Emmaus, Cedars-Sinai Extend Pact
- finance.yahoo.com — SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
- www.healio.com — Sustained investment in ‘meritorious’ research key to continued progress against cancer
- finance.yahoo.com — Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
-
Revolution Medicines sets annual price for pancreatic cancer drug Rasonque at $480,000
Revolution Medicines priced its FDA-approved pancreatic cancer drug, Rasonque, at approximately $480,000 per year, or $663 per tablet. The drug targets adults with metastatic pancreatic adenocarcinoma who have finished or cannot receive multiagent systemic therapy. Rasonque is a RAS(ON) multi selective inhibitor that stops tumor growth in over 90% of cases and increases median survival from 6.7 months to 13.2 months. While the treatment targets previously undruggable proteins, some patients report that insurance coverage takes weeks to become available.
Why it matters
Pancreatic cancer treatments often face high costs and limited efficacy. Rasonque represents a shift toward targeting specific proteins to extend life for patients with advanced disease.
What is confirmed
- Rasonque is a RAS(ON) multi selective inhibitor for adults with metastatic pancreatic adenocarcinoma.
- The drug increases median survival from 6.7 months to 13.2 months.
- Rasonque stops tumor growth in over 90% of cases.
- Revolution Medicines set the sticker price for the drug at about $480,000 a year, or $663 a tablet.
Still unconfirmed
- Early data indicates Rasonque may shrink tumors in patients with RAS mutant non small cell lung cancer.
- Insurance coverage for the drug may take weeks to become available despite FDA approval.
What to watch next
- Insurance provider coverage determinations for Rasonque
- Clinical trial results for RAS mutant non small cell lung cancer
confidence 100%Sources used for this update (4)
- www.medicalbrief.co.za — Staggering cost of pancreatic cancer pill the ‘new normal’
- finance.yahoo.com — Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
- www.mycentraloregon.com — Walking briskly may lower risk of death in some adults: Study
- www.financialcontent.com — U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
-
FDA-approved pancreatic cancer drug Rasonque faces insurance access hurdles
The FDA approved Rasonque, or daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who are ineligible for or have completed multiagent systemic therapy. Developed by Revolution Medicines, the drug is a RAS(ON) multi selective inhibitor that increases median survival from 6.7 months to 13.2 months and stops tumor growth in over 90% of cases. While the drug targets previously undruggable proteins, patients report that insurance coverage may take weeks to become available despite the approval. Early data also indicates the drug may shrink tumors in patients with RAS mutant non small cell lung cancer.
Why it matters
Pancreatic cancer has few effective late-stage options. Rasonque represents the first broad RAS targeted therapy for this malignancy. Its success may pave the way for other Ras-inhibitor candidates across various cancer types.
What is confirmed
- Rasonque, also known as daraxonrasib, is FDA approved for adults with metastatic pancreatic adenocarcinoma.
- The drug increases median survival from 6.7 months to 13.2 months.
- Clinical data shows the medication stops tumor growth in over 90% of cases.
- Daraxonrasib targets a broad range of RAS mutations and shows potential in shrinking lung cancer tumors.
Still unconfirmed
- The drug is a product that increasing numbers of patients cannot obtain.
What to watch next
- Insurance provider updates on coverage timelines for Rasonque.
- Clinical trial results for RAS mutant non small cell lung cancer.
- FDA approval of additional Ras-inhibitor drug candidates.
confidence 90%Sources used for this update (8)
- www.tovima.com — The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
- www.ibtimes.com.au — Pancreatic Cancer Drug Daraxonrasib Shows Early Promise Shrinking Tumors In Lung Cancer Trial
- www.statnews.com — A breakthrough pancreatic cancer drug won approval. They still struggle to access it
- www.chemistryworld.com — US approves pancreatic cancer treatment that targets ‘undruggable’ proteins
- www.goodnewsnetwork.org — FDA Immediately Approves Drug That’s Doubling Lifespan for Late Pancreatic Cancer Patients
- www.mycentraloregon.com — New drug shows promise in reducing COPD symptoms in smokers, clinical trials show
- news.ssbcrack.com — Study Identifies Drug Combination to Combat Treatment-Resistant Prostate Cancer
- ca.finance.yahoo.com — What Price Healthcare? RevMed’s Rasonque-The US Drug Pricing Paradox
-
FDA approves Rasonque for metastatic pancreatic cancer
The FDA approved Rasonque, also known as daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who are ineligible for multiagent systemic therapy or have completed one such therapy. Developed by Revolution Medicines, the drug is the first broad RAS targeted therapy for this cancer and the first of a new class called RAS(ON) multi selective inhibitors. Clinical data indicates the medication stops tumor growth in over 90% of cases and increases median survival from 6.7 months to 13.2 months. Recent study results published in the New England Journal of Medicine suggest the drug may also work for RAS mutant non small cell lung cancer.
Why it matters
Pancreatic cancer is among the deadliest forms of cancer. Rasonque targets tumors driven by RAS mutations. This approval introduces a new class of inhibitors to a treatment landscape with few survival advances.
What is confirmed
- The FDA approved Rasonque for adults with previously treated metastatic pancreatic adenocarcinoma.
- Rasonque is the first approved therapy from a class of RAS(ON) multi selective inhibitors targeting RAS mutations.
- Clinical data shows the drug increases median survival from 6.7 months to 13.2 months.
- The medication stops tumor growth in more than 90% of cases.
- Phase 1/2 clinical data for Rasonque in RAS mutant non small cell lung cancer was published in the New England Journal of Medicine.
Still unconfirmed
- The price of Rasonque may present a sustainability issue for future cancer drug launches.
What to watch next
- FDA approval decisions regarding the use of Rasonque for non small cell lung cancer.
- Long-term survival data from the RASolute 302 study.
confidence 100%Sources used for this update (6)
- abcnews.com — Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
- finance.yahoo.com — Pancreatic Cancer Drug Rasonque’s Price Indicates Sustainability Issue
- www.phillyvoice.com — Tommy John's legacy is the surgery that bears his name. But his willingness to embrace change is a lesson for all
- finance.yahoo.com — Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
- finance.yahoo.com — Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal
- oncodaily.com — Eileen M. O’Reilly and RASolute 302: A Rare Survival Advance in Pancreatic Cancer
-
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
The FDA approved daraxonrasib, a daily pill also known as Rasonque, for adults with metastatic pancreatic adenocarcinoma. The drug is intended for patients who are ineligible for multiagent systemic therapy or have already completed one systemic therapy. Clinical data shows the medication nearly doubles median survival from 6.7 months to 13.2 months and stops tumor growth in more than 90% of cases. Researchers describe the approval as a landmark development for treating one of the deadliest forms of cancer.
Why it matters
The drug targets a previously undruggable target through work by Dana-Farber and the University of Cincinnati. It serves as an alternative to chemotherapy for eligible patients.
What is confirmed
- The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma.
- The medication nearly doubles median survival from 6.7 months to 13.2 months.
- Daraxonrasib blocks tumor growth in over 90% of cases.
Still unconfirmed
- One-third of patients with advanced lung cancer saw tumors shrink in an early clinical trial.
- Researchers have called the drug a landmark development.
What to watch next
- Results from larger clinical trials regarding lung cancer efficacy
- Patient outcomes following wide commercial release of the drug
confidence 95%Sources used for this update (4)
- www.mycentraloregon.com — Radish sprout mix added to ongoing recall of sprouts linked to salmonella, E. coli outbreak
- www.medicalbrief.co.za — FDA approval of landmark pancreatic cancer drug hailed by experts
- www.nbcnews.com — Newly approved pancreatic cancer drug shows promise in lung cancer
- www.centralmaine.com — New pancreatic cancer drug gives South Portland man hope for longer life
-
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. The drug targets patients who have already undergone at least one systemic therapy or those ineligible for multiagent systemic therapy. Developed through efforts involving the University of Cincinnati and Dana-Farber, the medication addresses a previously undruggable target. Clinical data indicates the drug nearly doubles median survival from 6.7 months to 13.2 months and blocks tumor growth in over 90% of cases.
Why it matters
Pancreatic cancer has a high mortality rate, with 97% of patients dying within five years. This approval provides a first-of-its-kind treatment option for patients whose cancer has spread and progressed despite previous interventions.
What is confirmed
- The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma.
- Daraxonrasib is an oral multi-selective RAS(ON) inhibitor.
- The drug is for patients who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
- University of Cincinnati researchers helped develop the treatment.
Still unconfirmed
- Clinical trials showed the drug nearly doubled median survival from 6.7 months to 13.2 months.
- The medication blocks tumor growth in more than 90% of cases.
- High costs of the drug have caused affordability debates in India.
What to watch next
- Data on long-term survival rates beyond the initial trial period
- Pricing and insurance coverage decisions in the US
- Clinical results for daraxonrasib as a first-line therapy
confidence 90%Sources used for this update (5)
- www.news-medical.net — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
- www.news-medical.net — FDA approves daraxonrasib for patients with metastatic pancreatic cancer
- www.yahoo.com — INTERVIEW: Yale doctor discusses new pancreatic cancer drug
- www.cancertherapyadvisor.com — Tumor Treating Fields Extend Survival, but Uptake Has Been Slow
- www.wcpo.com — 'This is the beginning’ | UC researchers helped tackle an ‘undruggable’ target in pancreatic cancer
-
FDA Approves Daraxonrasib Pill for Advanced Pancreatic Cancer
The FDA granted expedited approval to Rasonque, a daily oral RAS inhibitor developed by Revolution Medicines and the University of Cincinnati Cancer Center for adults with advanced pancreatic cancer. Clinical trials showed the drug nearly doubled median survival from 6.7 months to 13.2 months. The medication blocks tumor growth in more than 90% of cases. While the drug offers a new treatment path for a disease where 97% of patients die within five years, its high cost has sparked affordability debates in India.
Why it matters
Pancreatic cancer is one of the deadliest malignancies with historically limited treatment options for metastatic stages. This approval marks the first pill capable of extending survival for this patient population.
What is confirmed
- The FDA approved daraxonrasib, marketed as RASONQUE, for adults with advanced pancreatic cancer.
- Clinical trials showed median survival increased to 13.2 months from 6.7 months.
- The medication is a once-daily oral RAS inhibitor.
- The drug was developed by Revolution Medicines and the University of Cincinnati Cancer Center.
Still unconfirmed
- The drug blocks tumor growth in more than 90% of pancreatic cancer cases.
- A month's supply of the drug costs nearly Rs 38 lakh in India.
What to watch next
- Pricing and insurance coverage determinations in the United States.
- Long-term survival data beyond the initial clinical trial period.
confidence 95%Sources used for this update (8)
- www.yahoo.com — Groundbreaking pancreatic cancer drug approved by FDA: What we know
- san.com — FDA approves pancreatic cancer drug tested on former lawmaker
- medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
- www.dynamitenews.com — New Pancreatic Cancer Pill Doubles Survival, But Rs 38 Lakh Price Sparks Debate in India
- www.rttnews.com — Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal
- www.gastroenterologyadvisor.com — FDA Approves First Pill to Extend Survival In Advanced Pancreatic Cancer
- www.bendsource.com — St. Charles Offers Groundbreaking Pancreatic Cancer Medication
- thetimesweekly.com — FDA approves breakthrough pancreatic cancer drug – an oncologist explains how daraxonrasib nearly doubles survival
-
FDA approves RASONQUE pancreatic cancer drug after survival rates nearly double
The FDA has approved daraxonrasib, marketed as RASONQUE, a targeted once-daily pill for advanced pancreatic cancer. The drug was approved more than six months ahead of schedule following trials that nearly doubled median survival to 13.2 months, compared to 6.7 months for patients receiving chemotherapy. Developed by Revolution Medicines with assistance from the University of Cincinnati Cancer Center, the medication is described as a breakthrough for a disease traditionally considered intractable. Anna Berkenblit of the Pancreatic Cancer Action Network stated the organization has never seen a benefit of this magnitude.
Why it matters
Pancreatic cancer is a deadly disease with historically limited treatment options. This approval introduces a targeted therapy designed to extend the lives of patients with advanced stages of the malignancy.
What is confirmed
- The FDA approved daraxonrasib, sold under the brand name RASONQUE, for the treatment of pancreatic cancer.
- Clinical trials showed the drug nearly doubled median survival to 13.2 months from 6.7 months seen with chemotherapy.
- The medication is a targeted therapy administered as a once-daily pill.
- Revolution Medicines developed the drug with help from the University of Cincinnati Cancer Center.
- The FDA issued the approval more than six months earlier than scheduled.
Still unconfirmed
- Former UF President Ben Sasse credits the drug with extending his life.
- A stage 4 patient in Maine reports the pill is buying him more time.
What to watch next
- Long-term survival data beyond the initial trial period
- Availability and insurance coverage for RASONQUE in the U.S.
- Development of similar targeted medicines for other pancreatic cancer mutations
confidence 95%Sources used for this update (19)
- WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
- The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
- CNN — Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
- Bloomberg — A Breakthrough Pancreatic Cancer Drug Marks a New Era for Treatment
- The Washington Post — FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
- Reuters — Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval
- Fox News — FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
- Scientific American — U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease
- WSJ — Opinion | A Pancreatic Cancer Revolution
- BBC — FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer
- WGME — Stage 4 Maine cancer patient says new FDA-approved pill is buying him time
- Pancreatic Cancer Action Network — FDA Approves RASONQUE™ (daraxonrasib)
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community